[A clinico-therapeutic study of the Bulgarian preparation fupiram]

The study includes 30 patients: 21 patients with various cardiac diseases which had led to chronic cardiac failure with well expressed edemas, 7 patients with liver cirrhosis and ascites, 2 patients with chronic glomerulonephritis and nephrotic syndrome. For 7 consecutive days the patients received fupyram or furanthril. In the morning, before breakfast, they received either 1 capsule fupyram (which is composed of amyloride hydrochloride 0.005 g and furezemide 0.04 g) or 1 tablet furanthril. In case of insufficient diuresis the daily dose was increased to 2 capsules fupyram (or 2 tablets furanthril respectively). In the patients with satisfactory diuretic effect the dose was reduced to 1 capsule (tablet) every other day or 2 capsules 2 times weekly after the second week. At the end of the 4-th week the general condition of the patients improved considerably. The diuresis increased, the body mass and the arterial pressure decreased. The potassium serum level increased from 4.4 +/- 0.3 mmol/l at the beginning of the treatment to 5.3 +/- 0.7 mmol/l. In 11 patients the potassium level reached values about 5.5 mmol/l. The drug fupyram exerts a pronounced diuretic efficacy. In the patients with preserved renal function fupyram does not change significantly the potassium serum level, but in patients with impaired renal function it can lead to hyperkalemia even after an unprolonged treatment.